Equity Analysis /
United States of America

US : Neurocrine Biosciences, Inc. - NBIX | Pre-Announced 4Q: Ingrezza Comes in Slightly Below Expectations; Volume Growth Remains Robust

    Danielle Brill
    CGS-CIMB
    7 January 2022
    Published by